

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[DEA # 179F]

**Controlled Substances: 1999
Aggregate Production Quotas**

AGENCY: Drug Enforcement Administration (DEA), Justice.

ACTION: Notice of final 1999 aggregate production quotas.

SUMMARY: This notice establishes final 1999 aggregate production quotas for controlled substances in Schedules I and II of the Controlled Substances Act (CSA). The DEA has taken into consideration comments received in response to a notice of the proposed revised aggregate production quotas for 1999 published August 20, 1999 (64 FR 45566). No comments were received in response to an interim notice establishing revised 1999 aggregate production quotas published August 27, 1999 (64 FR 46955). The interim notice is adopted with one change, as described below.

EFFECTIVE DATES: October 19, 1999.

FOR FURTHER INFORMATION CONTACT: Frank L. Sapienza, Chief, Drug and Chemical Evaluation Section, Drug Enforcement Administration, Washington, D.C. 20537, Telephone: (202) 307-7183.

SUPPLEMENTARY INFORMATION: Section 306 of the CSA (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for each basic class of controlled substance listed in Schedules I and II. This responsibility has been delegated to the

Administrator of the DEA by § 0.100 of Title 28 of the Code of Federal Regulations. The Administrator, in turn, has redelegated this function to the Deputy Administrator of the DEA pursuant to § 0.104 of Title 28 of the Code of Federal Regulations.

On August 20, 1999, a notice of the proposed revised 1999 aggregate production quotas for certain controlled substances in Schedules I and II was published in the Federal Register (64 FR 45566). All interested parties were invited to comment on or object to these proposed aggregate production quotas on or before September 20, 1999.

Several companies commented that the revised aggregate production quotas for amphetamine, dextropropoxyphene, dihydrocodeine, hydromorphone, meperidine, methadone (for sale), methadone intermediate, methylphenidate, and opium were insufficient to provide for the estimated medical, scientific, research and industrial needs of the United States, for export requirements and for the establishment and maintenance of reserve stocks. Two companies included information concerning potential increases in sales due to Y2K concerns.

DEA has taken into consideration the above comments along with the relevant 1998 year-end inventories, initial 1999 manufacturing quotas, 1999 export requirements, and actual and projected 1999 sales. Based on this information, the DEA has adjusted the final 1999 aggregate production quotas for amphetamine, desoxyephedrine, dextropropoxyphene, dihydrocodeine, hydromorphone, methadone (for sale), methadone intermediate and opium to

meet the legitimate needs of the United States.

Regarding meperidine and methylphenidate, the DEA has determined that no adjustments of the aggregate production quotas are necessary to meet the 1999 estimated medical, scientific, research and industrial needs of the United States.

In addition, on August 27, 1999, an interim notice establishing revised 1999 aggregate production quotas for amphetamine, codeine (for conversion), hydrocodone (for sale), hydrocodone (for conversion), morphine (for conversion), oxycodone (for sale) and thebaine was published in the **Federal Register** (64 FR 46955). All interested parties were invited to comment on or before September 27, 1999. No comments or objections were received regarding this interim notice. The aggregate production quota for amphetamine has been revised in response to comments received on 64 FR 45566. The remainder of the aggregate production quotas established in the interim notice are adopted without change.

Therefore, under the authority vested in the Attorney General by section 306 of the CSA of 1970 (21 U.S.C. 826), delegated to the Administrator of the DEA by § 0.100 of Title 28 of the Code of Federal Regulations, and redelegated to the Deputy Administrator pursuant to § 0.104 of Title 28 of the Code of Federal Regulations, the Deputy Administrator hereby orders that the final 1999 aggregate production quotas for the following controlled substances, expressed in grams of anhydrous acid or base, be established as follows:

Basic class	Established final 1999 quotas
Schedule I	
2,5-Dimethoxyamphetamine	10,501,000
2,5-Dimethoxy-4-ethylamphetamine (DOET)	2
3-Methylfentanyl	14
3-Methylthiofentanyl	2
3,4-Methylenedioxyamphetamine (MDA)	20
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)	30
3,4-Methylenedioxymethamphetamine (MDMA)	20
3,4,5-Trimethoxyamphetamine	2
4-Bromo-2,5-Dimethoxyamphetamine (DOB)	2
4-Bromo-2,5-Dimethoxyphenethylamine (2-CB)	2
4-Methoxyamphetamine	101,000
4-Methylaminorex	3
4-Methyl-2,5-Dimethoxyamphetamine (DOM)	2
5-Methoxy-3,4-Methylenedioxyamphetamine	2
Acetyl-alpha-methylfentanyl	2
Acetyldihydrocodeine	2
Acetylmethadol	7
Allylprodine	2
Alpha-acetylmethadol	7
Alpha-ethyltryptamine	2
Alphameprodine	2

Basic class	Established final 1999 quotas
Alpha-methadol	2
Alpha-methylfentanyl	2
Alpha-methylthiofentanyl	2
Alphaprodine	2
Aminorex	8
Benzylmorphine	2
Beta-acetylmethadol	2
Beta-hydroxy-3-methylfentanyl	2
Beta-hydroxyfentanyl	2
Betameprodine	2
Beta-methadol	2
Betaprodine	2
Bufotenine	2
Cathinone	9
Codeine-N-oxide	2
Diethyltryptamine	3
Difenoxin	9,000
Dihydromorphine	8
Dimethyltryptamine	4
Heroin	2
Hydroxypethidine	2
Lysergic acid diethylamide (LSD)	57
Mescaline	8
Methaqualone	17
Methcathinone	11
Morphine-N-oxide	2
N,N-Dimethylamphetamine	7
N-Ethyl-1-Phenylcyclohexylamine (PCE)	5
N-Ethylamphetamine	7
N-Hydroxy-3,4-Methylenedioxyamphetamine	4
Noracymethadol	2
Norlevorphanol	2
Normethadone	7
Normorphine	7
Para-fluorofentanyl	2
Pholcodine	2
Propiram	415,000
Psilocin	2
Psilocybin	2
Tetrahydrocannabinols	76,000
Thiofentanyl	2
Trimeperidine	2

Schedule II

1-Phenylcyclohexylamine	12
1-Piperidinocyclohexanecarbonitrile (PCC)	12
Alfentanil	3,900
Amobarbital	12
Amphetamine	9,174,000
Cocaine	251,000
Codeine (for sale)	58,248,000
Codeine (for conversion)	45,780,000
Desoxyephedrine (942,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product and 166,000 grams for methamphetamine)	1,108,000
Dextropropoxyphene	113,837,000
Dihydrocodeine	301,000
Diphenoxylate	846,000
Ecgonine	151,000
Ethylmorphine	13
Fentanyl	269,000
Glutethimide	2
Hydrocodone (for sale)	20,208,000
Hydrocodone (for conversion)	12,100,000
Hydromorphone	878,000
Isomethadone	12
Levo-alphaacetylmethadol (LAAM)	201,000
Levomethorphan	2
Levorphanol	15,000
Meperidine	11,207,000
Metazocine	1
Methadone (for sale)	8,753,000

Basic class	Established final 1999 quotas
Methadone (for conversion)	267,000
Methadone Intermediate	9,580,000
Methamphetamine (for conversion)	1,522,000
Methylphenidate	14,957,000
Morphine (for sale)	12,445,000
Morphine (for conversion)	94,900,000
Nabilone	2
Noroxymorphone (for sale)	25,000
Noroxymorphone (for conversion)	2,067,000
Opium	682,000
Oxycodone (for sale)	18,517,000
Oxycodone (for conversion)	106,000
Oxymorphone	166,000
Pentobarbital	22,037,000
Phencyclidine	40
Phenmetrazine	2
Phenylacetone	10
Secobarbital	1,155,000
Sufentanil	952
Thebaine	31,117,000

The Deputy Administrator further orders that aggregate production quotas for all other Schedules I and II controlled substances included in §§ 1308.11 and 1308.12 of Title 21 of the Code of Federal Regulations remain at zero.

The Office of Management and Budget has determined that notices of aggregate production quotas are not subject to centralized review under Executive Order 12866. This section has been analyzed in accordance with the principles and criteria contained in Executive Order 12612, and it has been determined that this matter does not have sufficient federalism implications to warrant the preparation of a Federalism Assessment.

The Deputy Administrator hereby certifies that this action will have no significant impact upon small entities whose interests must be considered under the Regulatory Flexibility Act, 5 U.S.C. 601 *et seq.* The establishment of aggregate production quotas for Schedules I and II controlled substances is mandated by law and by international treaty obligations. Aggregate production quotas apply to approximately 200 DEA registered bulk and dosage form manufacturers of Schedules I and II controlled substances. The quotas are necessary to provide for the estimated medical, scientific, research and industrial needs of the United States, for export requirements and the establishment and maintenance of reserve stocks. While aggregate production quotas are of primary importance to large manufacturers, their impact upon small entities is neither negative nor beneficial. Accordingly, the Deputy Administrator has determined

that this action does not require a regulatory flexibility analysis.

Dated: October 12, 1999.

Donnie R. Marshall,

Deputy Administrator.

[FR Doc. 99-27291 Filed 10-18-99 8:45 am]

BILLING CODE 4410-09-M

DEPARTMENT OF JUSTICE

Office of Juvenile Justice and Delinquency Prevention

[OJP(OJJDP)-1254]

RIN 1121-ZB88

Coalition of Juvenile Justice; Meeting

AGENCY: Office of Justice Programs,
Office of Juvenile Justice and
Delinquency Prevention, Justice.

ACTION: Notice of meeting.

SUMMARY: The Office of Juvenile Justice and Delinquency Prevention is announcing the meeting of the Coalition for Juvenile Justice.

DATES: The meeting dates are:

1. Thursday, November 11, 1999 from 8:00 a.m. until 6:00 p.m. (mountain time zone),
2. Friday, November 12, 1999 from 8:45 a.m. until 4:15 p.m. (mountain time zone),
3. Saturday, November 13, 1999 from 8:30 a.m. until 6:00 p.m. (mountain time zone),
4. Sunday, November 14, 1999 from 8:00 a.m. until 1:00 p.m. (mountain time zone).

ADDRESSES: All meetings will be held at the Little American Hotel, 500 South Main, Salt Lake City, Utah 84114.

FURTHER INFORMATION: For information about how to attend this meeting, contact Freida Thomas, 810 7th Street, NW, Washington, DC 20531; Telephone: (202) 307-5924 [This is not a toll-free number]; Facsimile: (202) 307-2819; E-mail: Freida@ojp.usdoj.gov.

SUPPLEMENTARY INFORMATION: The Coalition of Juvenile Justice, established pursuant to Section 9 of the Federal Advisory Committee Act, 5 U.S.C. App. II, is meeting to carry out its advisory functions under Section 5601 of the Juvenile Justice and Delinquency Prevention Act of 1974, as amended. The purpose of this meeting is to discuss and adopt recommendations from members regarding the committee's responsibility to advise the OJJDP Administrator, the President and the Congress about State perspectives on the operation of the OJJDP and Federal legislation pertaining to juvenile justice and delinquency prevention. This meeting will be open to the public.

Dated: October 12, 1999.

Shay Bilchik,

*Administrator, Office of Juvenile Justice and
Delinquency Prevention.*

[FR Doc. 99-27163 Filed 10-18-99; 8:45 am]

BILLING CODE 4410-18-P

NATIONAL SCIENCE FOUNDATION

Special Emphasis Panel in Civil and Mechanical Systems; Notice of Meeting

In accordance with the Federal Advisory Committee Act (Pub. L. 92-463, as amended), the National Science Foundation announces the following meeting: